PSA is routinely used in clinical guidelines as a biomarker for monitoring treatment response in prostate cancer, where a decline indicates a reduction in the viable tumor burden and rising PSA suggests non-response [2]. This evidence concerns the gene KLK3 and Familial prostate cancer.